A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance

被引:86
作者
El-Kareh, AW
Secomb, TW
机构
[1] Univ Arizona, ARL Microcirculat Div, Tucson, AZ 85724 USA
[2] Univ Arizona, Dept Physiol, Tucson, AZ USA
来源
NEOPLASIA | 2004年 / 6卷 / 02期
关键词
intraperitoneal delivery; chemotherapy; cisplatin; hyperthermia; continuous hyperthermic peritoneal perfusion;
D O I
10.1593/neo.03205
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
A theoretical model for the intraperitoneal (i.p.) delivery of cisplatin and heat to tumor metastases in tissues adjacent to the peritoneal cavity is presented. The penetration distance (the depth to which drug diffuses directly from the cavity into tissues) is predicted to be on the order of 0.5 mm. The model shows that exchange with the microvasculature has more effect than cellular uptake in limiting the penetration distance. Possible effects of hyperthermia are simulated, including increased cell uptake of drug, increased cell kill at a given level of intracellular drug, and decreased microvascular density. The model suggests that the experimental finding of elevated intracellular platinum levels up to a depth of 3 to 5 mm when drug is delivered i.p. by a heated infusion solution is due to penetration of heat to this distance, causing increased cell uptake of drug. Beyond a depth of about 0.5 mm, the drug is delivered mainly through the circulation. Use of sodium thiosulfate to deactivate systemic cisplatin may therefore be counterproductive when heat is delivered locally. The model suggests that i.p. delivery of heat, combined with systemic delivery of drug, may be as effective as i.p. delivery of heat and drug.
引用
收藏
页码:117 / 127
页数:11
相关论文
共 64 条
[1]
Changes in muscle blood flow distribution during hyperthermia [J].
Akyurekli, D ;
Gerig, LH ;
Raaphorst, GP .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1997, 13 (05) :481-496
[2]
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[3]
Bartlett DL, 1998, CANCER-AM CANCER SOC, V83, P1251, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1251::AID-CNCR27>3.3.CO
[4]
2-U
[5]
Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the Annual Meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001 [J].
Blakley, BW ;
Cohen, JI ;
Doolittle, ND ;
Muldoon, LL ;
Campbell, KC ;
Dickey, DT ;
Neuwelt, EA .
LARYNGOSCOPE, 2002, 112 (11) :1997-2001
[6]
Hyperthermic intraperitoneal chemoperfusion in the treatment of locally advanced intra-abdominal cancer [J].
Ceelen, WP ;
Hesse, U ;
de Hemptinne, B ;
Pattyn, P .
BRITISH JOURNAL OF SURGERY, 2000, 87 (08) :1006-1015
[7]
Chagnac A, 1999, J AM SOC NEPHROL, V10, P342
[8]
CHATO JC, 1987, HDB BIOENGINEERING
[9]
Malignant peritoneal mesothelioma treated by continuous hyperthermic peritoneal perfusion chemotherapy [J].
de Bree, E ;
Christodoulakis, M ;
Tsiftsis, D .
ANNALS OF ONCOLOGY, 2000, 11 (06) :753-756
[10]
Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure [J].
Dedrick, RL ;
Flessner, MF .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (07) :480-487